Myelodysplastic Syndromes: all 2,165 studies
Page 15 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- Study of TCP-ATRA for Adult Patients With AML and MDSCompletedNCT02273102Phase 1
- Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsStatus unknownNCT02272478Phase 2/3
- Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic ImpairmentWithdrawnNCT02269579Phase 2
- A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDSTerminatedNCT02267863Phase 1
- Phase I, Dose Escalation Study of DecitabineCompletedNCT02264873Phase 1
- Iron Overload and Transient Elastography in Patients With Myelodysplastic SyndromeCompletedNCT02262312
- Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic TransplantationNo longer availableNCT02258490
- Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT02250937Phase 2
- A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)TerminatedNCT02243124Phase 1
- Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic CancerStatus unknownNCT02240537Phase 1
- Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)CompletedNCT02233504Early Phase 1
- Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive ChemotherapyTerminatedNCT02226497Not applicable
- Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
- Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDSCompletedNCT02221310Phase 2
- Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic SyndromeCompletedNCT02212561Phase 1
- Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid TumorsCompletedNCT02211755Phase 1
- Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDSWithdrawnNCT02204020Phase 2
- Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-LigandsCompletedNCT02203825Phase 1
- A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedNCT02200380Phase 2
- Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)TerminatedNCT02198482Phase 2
- A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a ResponseCompletedNCT02197676Phase 2
- Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDSCompletedNCT02190695Phase 2
- Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood TransplantationCompletedNCT02188290
- Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)TerminatedNCT02181699Phase 1
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal DiseaseCompletedNCT02172768Phase 2
- Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological MalignanciesCompletedNCT02164071
- Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoLTerminatedNCT02147873Phase 2
- Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)TerminatedNCT02141477Phase 1
- Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in KoreaCompletedNCT02137629
- Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
- Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDSStatus unknownNCT02124174Phase 2
- Natural Killer Cells in Acute Leukaemia and Myelodysplastic SyndromeStatus unknownNCT02123836Phase 1
- Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesCompletedNCT02122081Phase 1
- SCT Plus Immune Therapy in Average Risk AML/MDSCompletedNCT02117297Phase 2
- Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic SyndromeCompletedNCT02117219Phase 1
- Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02117115Early Phase 1
- Red Blood Cell Transfusion Thresholds and QOL in MDSStatus unknownNCT02099669Not applicable
- Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)TerminatedNCT02093429Phase 1/2
- Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)CompletedNCT02085798
- Study of Molecular and Genetic Abnormalities in Patients With Myeloid NeoplasmsCompletedNCT02084563Phase 2
- Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell TransplantCompletedNCT02083250Phase 1
- A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)CompletedNCT02078609Phase 1
- Three Dosing Schedules of Oral Rigosertib in MDS PatientsWithdrawnNCT02075034Phase 1
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingNCT02061800Phase 1/2
- Prognostic Molecular Markers in Patients With Myelodysplastic SyndromeCompletedNCT02060409
- Occupational Status and Hematological DiseaseCompletedNCT02057185
- Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic SyndromeStatus unknownNCT02045654
- The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic SyndromeStatus unknownNCT02042482Phase 2/3
- Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02038816Phase 2
- Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02029950Phase 1
- Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDSCompletedNCT02018926Phase 1/2
- Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.CompletedNCT02017457Phase 2
- A Phase Ⅳ Study of Decitabine in Myelodysplastic SyndromeStatus unknownNCT02013102Phase 4
- Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single VaccinationStatus unknownNCT02007811Phase 1/2
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMACompletedNCT01993641Phase 2
- Evaluation of 3 Different Doses of IV BusulfanCompletedNCT01985061Phase 2
- Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood TransplantationStatus unknownNCT01983761Phase 1/2
- Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation TherapyCompletedNCT01956799
- Observational Evaluation of Infective Risk in Myelodysplastic Syndrome PatientsCompletedNCT01951430
- Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.CompletedNCT01933035
- Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineCompletedNCT01928537Phase 3
- Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineCompletedNCT01926587Phase 1/2
- Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic SyndromesCompletedNCT01913951Phase 1
- Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsTerminatedNCT01908387Phase 1
- Oral Rigosertib in Low Risk MDS Patients Refractory to ESAsCompletedNCT01904682Phase 2
- Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell TransplantCompletedNCT01904175
- Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT01895842Phase 1
- Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeWithdrawnNCT01892644Phase 2
- Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic SyndromeCompletedNCT01873703Phase 2
- PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous ThromboembolismCompletedNCT01855698
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01834248Phase 1
- Study of New RIC Regimen of BuFlu in Older and/or Intolerable PatientsStatus unknownNCT01828619
- Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine TherapyCompletedNCT01828346Phase 1/2
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
- Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid HemopathyCompletedNCT01819558Phase 1/2
- Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCTCompletedNCT01810120Phase 1/2
- Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeStatus unknownNCT01809392Phase 2/3
- Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell TransplantationStatus unknownNCT01806116Phase 4
- Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic SyndromeTerminatedNCT01795924Phase 1/2
- Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic SyndromeCompletedNCT01793675
- Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCTCompletedNCT01772953Phase 2
- Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
- Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01757639Phase 1
- Study of Hypotensive Hematopoietic Malignancy Patients' USCOM ReadingsCompletedNCT01755000Not applicable
- Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD ProphylaxisTerminatedNCT01749111Phase 3
- Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingNCT01746849Phase 2
- Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell TransplantActive, not recruitingNCT01744223Phase 1/2
- Spanish Registry of Erythropoietic Stimulating Agents StudyCompletedNCT01739452
- APG101 in Myelodysplastic SyndromeCompletedNCT01736436Phase 1
- Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.CompletedNCT01718379Phase 2
- Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus unknownNCT01716364Phase 1
- ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDSSuspendedNCT01709396Phase 2
- Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell TransplantationCompletedNCT01700751Phase 1
- Connect® Myeloid Disease RegistryTerminatedNCT01688011
- AML-MDS Novel Prognostic Tests Clinical StudyCompletedNCT01685619
- A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias InvolvingCompletedNCT01684150Phase 1
- Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCTCompletedNCT01683123
- Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic SyndromesCompletedNCT01674985Phase 1/2